ACTIVITY TITLE: Virtual Symposium: Addressing the Unmet Need of Diabetic Kidney Disease Progression: Beyond SGLT-2 Inhibitors and GLP-1 Ras
ACTIVITY FORMAT: Virtual Symposium
PROGRAM DESCRIPTION
Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons
with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and
renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure.
Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including
mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD. In
particular, non-steroidal mineralocorticoid receptor antagonists (MRAs) have shown promise in DKD, as demonstrated
in recent clinical trial results, and several phase III trials are ongoing.
During this symposium, experts will discuss recent and emerging clinical trial data with MRAs in DKD, particularly
non-steroidal MRAs. In addition, they will provide an overview about the underlying pathophysiology, how to identify
patients at high-risk, and the current management of DKD.
ESTIMATED TIME TO COMPLETE: 75 minutes
RELEASE DATE: December 26, 2019
EXPIRATION DATE: December 26, 2020
EDUCATIONAL GRANT SUPPORT
This educational activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
INTENDED AUDIENCE
This activity is designed for US-based endocrinologists, cardiologists, lipidologists, diabetologists,
gastroenterologists, hepatologists, PAs, registered nurses, and NPs
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
- Review the association and the pathophysiology between T2D and CKD, and the impact of concomitant CKD and T2D
on patient outcomes
- Employ the diagnostic criteria according to evidence-based guidelines for DKD in patients with T2DM at risk
for kidney disease progression
- Utilize current treatment options for patients with DKD based on identified benefits and risks, and current
guideline recommendations
- Review the efficacy and safety of emerging DKD treatments based on the latest evidence
FACULTY
George L. Bakris, MD (Chair)
- Professor of Medicine
- Director, ASH Comprehensive Hypertension Center
- University of Chicago Medicine
- Chicago, IL
Rajiv Agarwal, MD
-
Professor of Medicine
-
Indiana University School of Medicine & VA Medical Center
- Indianapolis, IN
Ileana L. Piña, MD, MPH, FAHA, FACC
-
Clinical Prof of Medicine, Central Michigan University
-
Director CVD Research and Academic Affairs
- Regional and National Director of Heart Failure
- Detroit Medical Center
- Detroit, MI
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute
for Medicine and CMHC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American
Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category
1
Credits™ Physicians should claim only the credit commensurate with the extent of their participation in the
activity.
CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated
for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
PHARMACIST ACCREDITATION STATEMENT
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hour(s) (.125
CEUs) of the Accreditation Council for Pharmacy Education.
This is an application-based activity. Universal Activity Numbers (UAN): JA4008162-9999-19-1024-H01-P
Upon completing the post-survey and the activity evaluation form, transcript information will be sent to the NABP
CPE Monitor Service within 4-6 weeks.
DIETICIAN ACCREDITATION STATEMENT
Postgraduate Institute for Medicine (CDR Provider #3631) is a Continuing Professional Education (CPE) Accredited
Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.5
Continuing Professional Education units (CPEUs) for completion of this activity.
This is a Level II activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in
a position to control the content of this activity to disclose any real or apparent conflict of interest (COO they
may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according
to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that
promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial
interest.
Faculty
Dr. Agarwal discloses the following:
- Royalty: UptoDate
- Consulting Fees: Boehringer, Bayer, Janssen, AstraZeneca, Diamedica Reata, Relypsa, Akebia
Dr. Bakris discloses the following:
- Consulting Fees: Merck, Novo Nordisk, Relypsa, Amgen
- Other: Janssen and Bayer-Steering committee and principal investigator on clinical trials in
nephropathy-fees go to U of Chicago
Dr. Piña discloses the following:
- Consulting Fees: Advisory Board – Relypsa, FDA CDRH Reviewer
Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not
indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled
indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily
represent the views of the planners. Please refer to the official prescribing information for each product for
discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and
their own professional development. The information presented in this activity is not meant to serve as a guideline
for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and
possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and
comparison with recommendations of other authorities.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 26,
2019 through December 26, 2020, participants must read the learning objectives and faculty disclosures and study
the educational activity.
If you wish to receive acknowledgment for completing this activity, please complete the post-survey and evaluation.
Upon completing, your certificate will be made available immediately.
Media: Internet
For questions about the accreditation of this activity, please visit www.pimed.com.
HARDWARE AND SOFTWARE REQUIREMENTS:
This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not
have these browsers, you can download Chrome here, Firefox here and Internet Explorer
here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB
RAM.